• 1
    Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76: 1899903
  • 2
    Watt KWK, Lee P-J, M’Timkulu T, Chan W-P, Loor R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 316670
  • 3
    Yousef GM, Diamandis EP. An overview of the kallikrein gene families in humans and other species: Emerging candidate tumour markers. Clin Biochem 2003; 36: 44352
  • 4
    Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrine Rev 2001; 22: 184204
  • 5
    Stephan C, Jung K, Diamandis EP et al. Prostate-specific antigen, its molecular forms, and other kallikrin markers for detection of prostate cancer. Urology 2002; 59: 28
  • 6
    Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 1990; 194: 75565
  • 7
    Lilja H, Abrahamsson P-A, Lundwall A. Semenogelin, the predominant protein in human semen. J Biol Chem 1989; 264: 1894900
  • 8
    Akiyama K, Nakamura T, Iwanaga S, Hara H. The chymotrypsin-like activity of human prostate-specific antigen γ-seminoprotein. FEBS Lett 1987; 225: 1894900
  • 9
    Lilja H, Oldbring J, Rannevik G, Laurell C-B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 2815
  • 10
    Denmeade SR, Lou W, Malm J, Lovgren J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate specific antigen. Cancer Res 1997; 57: 492430
  • 11
    Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 104653
  • 12
    Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996; 48: 31725
  • 13
    Lilja H, Piironen TP, Rittenhouse HG et al. Prostate-specific antigen. In VogelzangNJ, ShipleyWU, ScardinoPT, CoffeyDS eds, Comprehensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott, Williams & Wilkins Publishers, 2000: 63850
  • 14
    Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. J Biochem 1997; 272: 215828
  • 15
    Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Comm 1997; 238: 54955
  • 16
    Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997; 57: 31114
  • 17
    Herrala A, Kurkela R, Vihinen M, Kalkkinen N, Vihko P. Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms. Eur J Biochem 1998; 98: 323
  • 18
    Mikolajczyk AD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen is becoming more complex. Urology 2002; 59: 797802
  • 19
    Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. Characterization of hK4 (protease), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001; 40: 153418
  • 20
    Takayama TK, Carter CA, Deng T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001; 40: 167987
  • 21
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 115661
  • 22
    Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumour marker for adenocarcinoma of the prostate. J Urol 1991; 145: 90723
  • 23
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 28994
  • 24
    Morgan TO, Jacobsen SJ, McCarthy WF et al. Age-specific ranges for serum prostate-specific antigen in black men. N Engl J Med 1996; 335: 30410
  • 25
    Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58: 4116
  • 26
    Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 1991; 37: 161825
  • 27
    Stenman UH, Leinonen J, Alfthan H et al. A complex between prostate specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 2226
  • 28
    Otto A, Bar J, Birkenmeier G. Prostate-specific antigen forms complexes with human alpha 2-macrogoglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein. J Urol 1998; 159: 297303
  • 29
    Chen Z, Komatsu K, Prestigiacomo A, Stamey TA. Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin. J Urol 1996; 156: 135763
  • 30
    Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate-specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159: 512
  • 31
    Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 15427
  • 32
    Zhang WM, Leinonen J, Kalkkinen N, Stenman UH. Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. Prostate 1997; 33: 8796
  • 33
    Huber PR, Mattarelli G, Strittmatter B, Van Steenbrugge GJ, Schmid H-P, Maurer A. In vivo and in vitro complex formation of prostate specific antigen with α1-antichymotrypsin. Prostate 1995; 27: 16675
  • 34
    Bjork T, Ljungberg B, Piironen T et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity limited elimination of PSA complexed to alpha1-antichymotrypsin from serum. Urology 1998; 51: 5762
  • 35
    Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH. Determination of prostate-specific antigen complexed to alpha (2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000; 56: 26772
  • 36
    Kanoh Y, Ohtani N, Ohara T et al. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes. Oncol Report 2001; 8: 5159
  • 37
    Bjartell A, Bjork T, Matikainen MT et al. Production of alpha-1 antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993; 42: 50210
  • 38
    Bjork T, Bjartell A, Abrahamson PA et al. Alpha-1 antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994; 43: 42734
  • 39
    Tanaka M, Suzuki Y, Takaoka K, Murakami S, Suzuki N, Shimazaki J. Immunohistochemical finding of alpha-1 antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer. Int J Urol 1999; 6: 6006
  • 40
    Wu G, Lilja H, Cockett ATK, Gershagen S. Cloning and characterization of the α1-antichymotrypsin produced by human prostate tissue. Prostate 1998; 34: 15561
  • 41
    Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003; 3: 5663
  • 42
    Jung K, Brux B, Lein M et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin Chem 2000; 46: 4754
  • 43
    Mikolajczyk SD, Grauer LS, Millar LS et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997; 50: 7104
  • 44
    Mikolajczyk SD, Millar LS, Wang TJ et al. ‘BPSA’, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000; 55: 415
  • 45
    Marks LS, Linton HJ, Gasior CL et al. BPSA is a potential serum marker for benign prostatic hyperplasia (BPH). J Urol 2001; 165: 266 (Abstract)
  • 46
    Peter J, Unverzagt C, Krogh TN et al. Identification of precursor forms of prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001; 61: 95762
  • 47
    Mikolajczyk SD, Marker KM, Millar LS et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001; 61: 695863